\-\ Texto\\:\\ \ \(0\)\
\-\ left\\-sided\\ foot\\ drop\\.\ \(0\)\
\-\ patient\\ underwent\\ resection\\ of\\ the\\ mass\\ and\\ is\\ being\\ treated\\ with\\ phenytoin\\ for\\ seizure\\ prophylaxis\\.\\ \\ the\\ patient\\ has\\ had\\ a\\ follow\\ up\\ mri\\ to\\ assess\\ for\\ residual\\ tumor\\.\ \(0\)\
\-\ noncontrast\\ head\\ ct\\ demonstrates\\ a\\ large\\ right\\ temporal\\ mass\\ with\\ subfalcine\\ and\\ uncal\\ herniation\\ from\\ right\\ to\\ left\\.\\ \\ the\\ mass\\ is\\ heterogenous\\ with\\ several\\ curvilinear\\ areas\\ of\\ calcification\\ and\\ surrounding\\ vasogenic\\ edema\\.\\ \\ \ \(0\)\
\-\ the\\ mri\\ images\\ again\\ demonstrate\\ signal\\ heterogenity\\ with\\ partial\\ central\\ necrosis\\.\\ \\ the\\ lesion\\ produces\\ moderate\\-to\\-severe\\ mass\\ effect\\ with\\ effacement\\ of\\ the\\ left\\ lateral\\ ventricle\\,\\ and\\ subfalcine\\ and\\ transtentorial\\ herniation\\.\ \(0\)\
\-\ glioblastoma\\ multiforme\ \(8\)\
\-\ astrocytoma\ \(206\)\
\-\ oligodendroglioma\ \(21\)\
\-\ metastastic\\ disease\\,\\ partially\\ hemorrhagic\\ lesion\ \(0\)\
\-\ primary\\ cns\\ lymphoma\ \(0\)\
\-\ 44\\-year\\ old\\ woman\\ with\\ several\\ week\\ history\\ of\\ headaches\\.\\ \\ patient\\ developed\\ a\\ left\\-sided\\ foot\\ drop\\ approximately\\ one\\-week\\ prior\\ to\\ presenting\\ to\\ her\\ physician\\.\ \(0\)\
\-\ glioblastoma\\ multiforme\\ is\\ the\\ most\\ common\\ primary\\ brain\\ tumor\\.\\ \\ approximately\\ 50\\%\\ of\\ astrocytomas\\ are\\ gbms\\.\\ \\ these\\ tumors\\ normally\\ occur\\ in\\ patients\\ over\\ 50\\.\\ \\ this\\ patient\\,\\ at\\ 44\\-years\\ old\\,\\ is\\ at\\ the\\ younger\\ end\\ of\\ the\\ age\\ spectrum\\.\ \(0\)\
\-\ these\\ lesions\\ are\\ varied\\ in\\ their\\ appearance\\ secondary\\ to\\ their\\ multiple\\ pathologic\\ forms\\.\\ \\ however\\,\\ they\\ typically\\ are\\ highly\\ vascular\\ with\\ edema\\ and\\ hemorrhage\\ being\\ common\\.\\ \\ they\\ demonstrate\\ strong\\,\\ heterogeneous\\ enhancement\\.\\ \\ calcification\\ is\\ rare\\,\\ although\\ this\\ lesion\\ did\\ demonstrate\\ several\\ areas\\ of\\ calcification\\.\ \(0\)\
\-\ this\\ lesion\\ does\\ not\\ cross\\ the\\ corpus\\ callosum\\,\\ although\\ it\\ is\\ one\\ of\\ two\\ intracranial\\ neoplasms\\,\\ along\\ with\\ primary\\ cns\\ lymphma\\,\\ that\\ can\\ extend\\ through\\ white\\ matter\\ tracts\\ and\\ involve\\ both\\ hemispheres\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ subfalcine\\:\\ 0\\.04896942354114626\ \(0\)\
\-\ drop\\:\\ 0\\.03955015310133146\ \(0\)\
\-\ multiforme\\:\\ 0\\.03733361520493564\ \(0\)\
\-\ glioblastoma\\:\\ 0\\.035373267366866065\ \(0\)\
\-\ calcification\\:\\ 0\\.03498254456906536\ \(0\)\
\-\ heterogenity\\:\\ 0\\.03314104670664097\ \(0\)\
\-\ 44\\-year\\:\\ 0\\.03314104670664097\ \(0\)\
\-\ 44\\-years\\:\\ 0\\.03314104670664097\ \(0\)\
\-\ lymphma\\:\\ 0\\.03314104670664097\ \(0\)\
\-\ cns\\:\\ 0\\.03287870050733971\ \(0\)\
\-\ left\\-sided\\:\\ 0\\.03165675366901057\ \(0\)\
\-\ several\\:\\ 0\\.03098225002694422\ \(0\)\
\-\ metastastic\\:\\ 0\\.030535230238370497\ \(0\)\
\-\ phenytoin\\:\\ 0\\.029010925320670632\ \(0\)\
\-\ gbms\\:\\ 0\\.029010925320670632\ \(0\)\
\-\ herniation\\:\\ 0\\.028608143833610843\ \(0\)\
\-\ primary\\:\\ 0\\.02854944657401161\ \(0\)\
\-\ their\\:\\ 0\\.02812289179498249\ \(0\)\
\-\ moderate\\-to\\-severe\\:\\ 0\\.027929413770100026\ \(0\)\
\-\ one\\-week\\:\\ 0\\.027929413770100026\ \(0\)\
\-\ transtentorial\\:\\ 0\\.0270905282388436\ \(0\)\
\-\ 50\\.\\:\\ 0\\.0270905282388436\ \(0\)\
\-\ foot\\:\\ 0\\.026558757106981277\ \(0\)\
\-\ uncal\\:\\ 0\\.02640510885240016\ \(0\)\
\-\ lesion\\:\\ 0\\.026173762796999317\ \(0\)\
\-\ varied\\:\\ 0\\.024880803934700293\ \(0\)\
\-\ they\\:\\ 0\\.023149970875844406\ \(0\)\
\-\ being\\:\\ 0\\.022389383284214723\ \(0\)\
\-\ astrocytomas\\:\\ 0\\.022274987466429825\ \(0\)\
\-\ demonstrate\\:\\ 0\\.02217803166916963\ \(0\)\
\-\ although\\:\\ 0\\.02169871639531281\ \(0\)\
\-\ areas\\:\\ 0\\.02161915166350426\ \(0\)\
\-\ tracts\\:\\ 0\\.021520586355669856\ \(0\)\
\-\ prophylaxis\\:\\ 0\\.02011196436528861\ \(0\)\
\-\ produces\\:\\ 0\\.019884052253196755\ \(0\)\
\-\ cross\\:\\ 0\\.019884052253196755\ \(0\)\
\-\ approximately\\:\\ 0\\.019878329522974306\ \(0\)\
\-\ oligodendroglioma\\:\\ 0\\.018830285466902925\ \(0\)\
\-\ younger\\:\\ 0\\.01874765799803535\ \(0\)\
\-\ forms\\:\\ 0\\.01866680760246782\ \(0\)\
\-\ strong\\:\\ 0\\.01866680760246782\ \(0\)\
\-\ spectrum\\:\\ 0\\.01858765944758875\ \(0\)\
\-\ curvilinear\\:\\ 0\\.01851014333028523\ \(0\)\
\-\ edema\\:\\ 0\\.018172357063393162\ \(0\)\
\-\ mass\\:\\ 0\\.01787159408943706\ \(0\)\
\-\ effacement\\:\\ 0\\.017625503905719573\ \(0\)\
\-\ vasogenic\\:\\ 0\\.01739046496969952\ \(0\)\
\-\ noncontrast\\:\\ 0\\.01716926008239526\ \(0\)\
\-\ hemispheres\\:\\ 0\\.017115934386936777\ \(0\)\
\-\ common\\:\\ 0\\.016814039187642082\ \(0\)\
\-\ these\\:\\ 0\\.016720636781637894\ \(0\)\
\-\ heterogenous\\:\\ 0\\.01648384069595182\ \(0\)\
\-\ callosum\\:\\ 0\\.01648384069595182\ \(0\)\
\-\ neoplasms\\:\\ 0\\.016351918441022236\ \(0\)\
\-\ end\\:\\ 0\\.016308953419128913\ \(0\)\
\-\ assess\\:\\ 0\\.016101198988019705\ \(0\)\
\-\ extend\\:\\ 0\\.016101198988019705\ \(0\)\
\-\ residual\\:\\ 0\\.015942885133319984\ \(0\)\
\-\ normally\\:\\ 0\\.015828376834505286\ \(0\)\
\-\ corpus\\:\\ 0\\.015828376834505286\ \(0\)\
\-\ highly\\:\\ 0\\.015470067887872486\ \(0\)\
\-\ again\\:\\ 0\\.015436045949827684\ \(0\)\
\-\ physician\\:\\ 0\\.01514295744806185\ \(0\)\
\-\ involve\\:\\ 0\\.01514295744806185\ \(0\)\
\-\ hemorrhagic\\:\\ 0\\.01498949130324886\ \(0\)\
\-\ tumor\\:\\ 0\\.014979190237675272\ \(0\)\
\-\ mri\\:\\ 0\\.014761472593343006\ \(0\)\
\-\ partially\\:\\ 0\\.014700164080932589\ \(0\)\
\-\ seizure\\:\\ 0\\.014205134667491988\ \(0\)\
\-\ pathologic\\:\\ 0\\.014061445897491245\ \(0\)\
\-\ intracranial\\:\\ 0\\.01357711179281843\ \(0\)\
\-\ are\\:\\ 0\\.013137675254093251\ \(0\)\
\-\ presenting\\:\\ 0\\.013093231694365146\ \(0\)\
\-\ patient\\:\\ 0\\.012881081667915607\ \(0\)\
\-\ temporal\\:\\ 0\\.012864251419602016\ \(0\)\
\-\ partial\\:\\ 0\\.012847201964093027\ \(0\)\
\-\ is\\:\\ 0\\.012683250640256969\ \(0\)\
\-\ necrosis\\:\\ 0\\.012680829749792122\ \(0\)\
\-\ matter\\:\\ 0\\.012648420941356382\ \(0\)\
\-\ astrocytoma\\:\\ 0\\.01247500074689209\ \(0\)\
\-\ rare\\:\\ 0\\.01247500074689209\ \(0\)\
\-\ developed\\:\\ 0\\.01236866723622073\ \(0\)\
\-\ headaches\\:\\ 0\\.012279858417561195\ \(0\)\
\-\ 50\\:\\ 0\\.012221797055051897\ \(0\)\
\-\ tumors\\:\\ 0\\.012066602848385342\ \(0\)\
\-\ occur\\:\\ 0\\.012052806875118565\ \(0\)\
\-\ ventricle\\:\\ 0\\.012039061344279803\ \(0\)\
\-\ heterogeneous\\:\\ 0\\.011812763747349644\ \(0\)\
\-\ did\\:\\ 0\\.011599318199221517\ \(0\)\
\-\ effect\\:\\ 0\\.011374279146876859\ \(0\)\
\-\ typically\\:\\ 0\\.01133994650190215\ \(0\)\
\-\ underwent\\:\\ 0\\.01102329336645947\ \(0\)\
\-\ does\\:\\ 0\\.010960981467609047\ \(0\)\
\-\ week\\:\\ 0\\.01090983239973018\ \(0\)\
\-\ this\\:\\ 0\\.010839893383242101\ \(0\)\
\-\ hemorrhage\\:\\ 0\\.010692693925473817\ \(0\)\
\-\ white\\:\\ 0\\.010654527115458712\ \(0\)\
\-\ along\\:\\ 0\\.010616743897964347\ \(0\)\
\-\ central\\:\\ 0\\.010570042694962251\ \(0\)\
\-\ surrounding\\:\\ 0\\.01056077167054423\ \(0\)\
\-\ vascular\\:\\ 0\\.010533094992194347\ \(0\)\
\-\ follow\\:\\ 0\\.0102075168118287\ \(0\)\
\-\ \\,\\:\\ 0\\.010177070132228848\ \(0\)\
\-\ resection\\:\\ 0\\.010018479907970746\ \(0\)\
\-\ age\\:\\ 0\\.009777858366707918\ \(0\)\
\-\ brain\\:\\ 0\\.009666735050010382\ \(0\)\
\-\ her\\:\\ 0\\.009659442325131336\ \(0\)\
\-\ treated\\:\\ 0\\.009615980586781425\ \(0\)\
\-\ two\\:\\ 0\\.009200493374496261\ \(0\)\
\-\ appearance\\:\\ 0\\.009187618709528727\ \(0\)\
\-\ lymphoma\\:\\ 0\\.009181197873644683\ \(0\)\
\-\ through\\:\\ 0\\.009123898565491987\ \(0\)\
\-\ head\\:\\ 0\\.009111283122458255\ \(0\)\
\-\ secondary\\:\\ 0\\.008981315663566945\ \(0\)\
\-\ however\\:\\ 0\\.00894499269021455\ \(0\)\
\-\ one\\:\\ 0\\.008705757080115202\ \(0\)\
\-\ at\\:\\ 0\\.008704986111516037\ \(0\)\
\-\ up\\:\\ 0\\.008638523124263997\ \(0\)\
\-\ enhancement\\:\\ 0\\.008610860023018932\ \(0\)\
\-\ lesions\\:\\ 0\\.008599851527608825\ \(0\)\
\-\ signal\\:\\ 0\\.008470204249145784\ \(0\)\
\-\ patients\\:\\ 0\\.008314190223180548\ \(0\)\
\-\ prior\\:\\ 0\\.008248544256399861\ \(0\)\
\-\ both\\:\\ 0\\.00820375936348166\ \(0\)\
\-\ over\\:\\ 0\\.008179107481729182\ \(0\)\
\-\ to\\:\\ 0\\.008027596023364402\ \(0\)\
\-\ \\%\\:\\ 0\\.007493688095285743\ \(0\)\
\-\ woman\\:\\ 0\\.007420687772514685\ \(0\)\
\-\ most\\:\\ 0\\.007416673465143142\ \(0\)\
\-\ can\\:\\ 0\\.007286550197252141\ \(0\)\
\-\ it\\:\\ 0\\.007221234528319611\ \(0\)\
\-\ left\\:\\ 0\\.007188761423104622\ \(0\)\
\-\ large\\:\\ 0\\.007024595608387517\ \(0\)\
\-\ demonstrates\\:\\ 0\\.007017372938545811\ \(0\)\
\-\ lateral\\:\\ 0\\.006942361073776505\ \(0\)\
\-\ had\\:\\ 0\\.006931766237747023\ \(0\)\
\-\ right\\:\\ 0\\.006779185782785088\ \(0\)\
\-\ multiple\\:\\ 0\\.0067661879830047695\ \(0\)\
\-\ old\\:\\ 0\\.006578455615505674\ \(0\)\
\-\ images\\:\\ 0\\.006162646210335917\ \(0\)\
\-\ has\\:\\ 0\\.006032706655993526\ \(0\)\
\-\ that\\:\\ 0\\.005548799731424148\ \(0\)\
\-\ for\\:\\ 0\\.005482016155208384\ \(0\)\
\-\ disease\\:\\ 0\\.005250893012089113\ \(0\)\
\-\ the\\:\\ 0\\.005197341530211496\ \(0\)\
\-\ from\\:\\ 0\\.004761036515617339\ \(0\)\
\-\ and\\:\\ 0\\.0047370790982162745\ \(0\)\
\-\ not\\:\\ 0\\.004642175457676449\ \(0\)\
\-\ ct\\:\\ 0\\.004493622757112943\ \(0\)\
\-\ a\\:\\ 0\\.004472930095698511\ \(0\)\
\-\ history\\:\\ 0\\.004436896758297306\ \(0\)\
\-\ with\\:\\ 0\\.0035189225891696157\ \(0\)\
\-\ of\\:\\ 0\\.0035038737082101782\ \(0\)\
\-\ in\\:\\ 0\\.003168400226618458\ \(0\)\
\-\ \\.\\:\\ 0\\.002268767344567243\ \(0\)\
